Brief: Avecho Biotechnology Says Receives Ethics Approval For Amendments To Phase III Insomnia Clinical Trial
06/03/2024 22:35
March 7 (Reuters) - Avecho Biotechnology Ltd AVE.AX :
* RECEIVES ETHICS APPROVAL FOR AMENDMENTS TO PHASE III
INSOMNIA
CLINICAL TRIAL
Further company coverage: AVE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avecho Biotechnology
See all newsBrief: Avecho Biotechnology Seeks Trading Halt
Australia's Avecho Biotechnology falls on discounted placement
Brief: Avecho Biotechnology Raises A$2.5M Via Placement
Brief: Avecho And Sandoz Enter Exclusive License And Development Agreement
Brief: Avecho Biotechnology Seeks Trading Halt Pending Release Of Information About License And Development Agreement